STAAR Surgical Company (STAA)

STAAR Surgical's stock price has been significantly impacted by several key events over the past six months, resulting in a -36.54% change over this period and a -25.23% change over the last year. The proposed merger with Alcon was terminated after not receiving the necessary stockholder votes. The company experienced significant sales declines in China during Q1 and Q2 2025 due to distributors reducing their inventory levels. STAAR Surgical reported Q1 2025 EPS at -$1.10, missing forecasts, and a net loss of $(16.8) million in Q2 2025.

Demand for STAAR Surgical's products exhibits some seasonality, particularly in certain key markets. Historically, the market in China appears to normalize in time for the seasonally strong summer months. The company has also noted that the distributor ordering cycle in China begins in May ahead of this busy summer period. Implied volatility has historically tended to rise most in February and decline to its lowest levels in August. The company anticipated minimal China ICL sales in the first half of 2025, with an expected rebound in the second half, partly dependent on the 2025 summer high season in China leading to increased demand.

STAAR Surgical Co. is a global leader in ophthalmic surgery, specializing in implantable lenses and delivery systems, operating within the medical devices sector. Their primary products are Implantable Collamer® Lenses (ICLs), including the EVO Visian ICL™ family, used in refractive surgery to correct vision disorders. The company has phased out IOLs for cataract surgery to focus on ICLs, which accounted for approximately 95% of its total sales in fiscal year 2022.

STAAR Surgical has a significant global presence, selling its products in over 75 countries, with direct distribution in key markets and a combination of direct and independent distribution in other regions. A substantial portion of the company's revenue is generated outside the United States, accounting for 95% of total sales in fiscal year 2022 and 94% in fiscal year 2024. China is a major market, representing approximately 51% of consolidated net sales in fiscal year 2024. The company's global administrative offices and principal manufacturing facility are located in Monrovia, California, with additional facilities in Switzerland and Japan.

STAAR Surgical maintains a strong brand reputation rooted in its dedication to ophthalmic surgery and its innovative Implantable Collamer® Lens (ICL) technology. The company's mission is to provide visual freedom to patients, and its EVO ICLs are clinically proven to deliver safe, long-term vision correction. STAAR Surgical has focused on enhancing surgeon confidence and adoption through initiatives like the launch of STAAR University and the opening of an EVO Experience Center. The company also announced a milestone strategic agreement with IQ Laser Vision in the U.S. in May 2024, aiming to make EVO ICL lenses a primary option for patients and nearly double their volume in the next 12 months.

STAAR Surgical Company's ownership is predominantly institutional, with 366 institutional owners and shareholders holding a total of 58,220,917 shares. Major institutional owners include Broadwood Capital Inc., BlackRock, Inc., and Vanguard Group Inc. Broadwood Capital Inc. is a significant and influential shareholder, actively participating in major decisions such as the proposed acquisition by Alcon.